Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. We are committed to investing in innovative treatments in diabetes and obesity, two of the biggest challenges facing the NHS. We believe that our medicines can make an important contribution to helping the NHS improve patient outcomes in these two areas. Our most recent commitment is a landmark research collaboration focused on Type 2 diabetes with the University of Oxford which will invest £115m over 10 years and employ up to 100 Novo Nordisk researchers in the UK.
For further information please contact us: +44 (0) 1293 613555